Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Total Liabilities (2016 - 2025)

Dexcom (DXCM) has disclosed Total Liabilities for 16 consecutive years, with $3.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 17.98% to $3.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 billion, a 17.98% decrease, with the full-year FY2025 number at $3.6 billion, down 17.98% from a year prior.
  • Total Liabilities was $3.6 billion for Q4 2025 at Dexcom, up from -$2.7 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.8 billion in Q2 2025 to a low of -$2.7 billion in Q3 2025.
  • A 5-year average of $1.4 billion and a median of $2.7 billion in 2021 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 337.23% in 2023; the steepest drop was 177.87% in 2023.
  • Dexcom's Total Liabilities stood at $2.6 billion in 2021, then rose by 24.8% to $3.3 billion in 2022, then increased by 28.71% to $4.2 billion in 2023, then grew by 4.43% to $4.4 billion in 2024, then fell by 17.98% to $3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Total Liabilities are $3.6 billion (Q4 2025), -$2.7 billion (Q3 2025), and $4.8 billion (Q2 2025).